In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy

Indian Journal of Cancer

Volumn 44, Issue 4, 2007, Pages 142-146

  Pathak, K A ^a   Juvekar, A S ^b   Radhakrishnan, D K ^b   Deshpande, M S ^a   Pai, V R ^a   Chaturvedi, P ^a   Pai, P S ^a   Chaukar, D A ^a   D'Cruz, A K ^a   Parikh, P M ^a  

^a TATA MEMORIAL HOSPITAL   (India)

^b ADVANCED CENTRE FOR TREATMENT RESEARCH AND EDUCATION IN CANCER   (India)

Author keywords

Assay; Chemotherapy; Cisplatin; Fluorouracil; Methotrexate; Neoplasm oral; Response

Indexed keywords

EID: 40749083605     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509X.39376     Document Type: Article

References (28)

1. th ed. Lea and Feviger: Philadelphia; 1997.
2. Lamont EB, Vokes EE. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol 2001;2:261-9.
3. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III and IV head and neck carcinoma: A study by the Grouppo di Studio sui Tumouridella Testa del Collo. J Natl Cancer Inst 1994;86:265-72.
4. Ensley JF, Jacobs JR, Weaver A, Kinzie J, Crissman J, Kish JA, et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984;54:811-4.
5. Furukawa T, Kubota T, Hoffman RM. Clinical application of histoculture drug response assay. Clin Cancer Res 1995; 1:305-11.
6. Kubota T, Furukawa T, Kitajima M. High clinical predictability of histoculture drug response assay (HDRA) for drug-sensitivity of cancer of digestive organs. Gan To Kagako Ryoho 1993;20:461-6.
7. Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, et al. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 2000;20:2049-54.
8. Hirano Y, Ushiyama T, Suzuki K, Fujita K. Clinical application of an In vitro chemosensitivity test, the histoculture drug response assay, to urological cancers: Wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res 1999;27:483-8.
9. Nakamura J, Imai E, Yoshihama M, Sasano H, Kubota T. Histoculture drug response assay, a possible examination system for predicting the antitumour effect of aromatase inhibitors in patients with breast cancer. Anticancer Res 1998; 18:125-8.
10. Robbins KT, Varki NM, Stornilo AM, Hoffman H, Hoffman RM. Drug response of head and neck tumours in native-state histocultrue. Arch Otolaryngol Head Neck Surg 1991;117:83-6.
11. Robbins KT, Connors KM, Stornilo AM, Hanchett C, Hoffman RM. Sponge gel supported Histoculture drug response assay for head and neck cancer: Correlation with clinical response to cisplatin. Arch Otolaryngol Head Neck Surg 1994;120:288-92.
12. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002;24:437-42.
13. Robbins KT, Varki NM, Storniolo AM, Hoffman H, Hoffman RM. Drug response of head and neck tumours in native-state histoculture. Arch Otolaryngol Head Neck Surg 1991;117:83-6.
14. Ariyoshi Y, Shimahara M, Tanigawa N. Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol 2003;39:701-7.
15. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, et al. High in vitro - in vivo correlation of drug response using sponge gel supported three-dimensional histoculture and MTT end point. Int J Cancer 1992;51:489-98.
16. Grau JJ, Estape J, Blanch JL, Vilalta A, Castro V, Biete A, et al. Neoadjuvant and adjuvant chemotherapy in the multidisciplinary treatment of oral cancer stage III or IV. Eur J Cancer B Oral Oncol 1996;32B:238-41.
17. Basu S, Khanra M, Dash B, Majumdar J, Biswas J, Chaudhuri P. The role of neoadjuvant and adjuvant chemotherapy regimens consisting of different combinations of drugs in the treatment of advanced oral cancer. Med Oncol 1999;16:199-203.
18. Hill BT, Price LA. Lack of survival advantage in patients with advanced squamous cell carcinomas of the oral cavity receiving neoadjuvant chemotherapy prior to local therapy, despite achieving an initial high clinical complete remission rate. Am J Clin Oncol 1994;17:1-5.
19. Okura M, Hiranuma T, Adachi T, Ogura T, Aikawa T, Yoshioka H, et al. Induction chemotherapy is associated with an increase in the incidence of locoregional recurrence in patients with carcinoma of the oral cavity: Results from a single institution. Cancer 1998;82:804-15.
20. Mazeron JJ, Martin M, Brun B, Grimard L, Lelievre G, Vergnes L, et al. Induction chemotherapy In head and neck cancer: Results of a phase III trial. Head Neck 1992;14:85-91.
21. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer. Laryngoscope 1988;98:1205-11.
22. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data: Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
23. Tannock IF, Browman G. Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck carcinoma. J Clin Oncol 1986;4:1121-6.
24. Jacobs JR, Pajak TF, Kinzie J, Al-Sarraf M, Davis L, Hanks GA, et al. Induction chemotherapy in advanced head and neck cancer: A radiation therapy oncology group study. Arch Otolaryngol Head Neck Surg 1987;113:193-7.
25. Itaya M, Yoshimoto J, Kojima K, Futagawa S. Usefulness of p53 protein, bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumours. Oncol Rep 1999;:675-82.
26. Kubota T, Sasano H, Abe O, Nakao I, Kawamura E, Saito T, et al. Potential of histoculture drug response assay to contribute to cancer patient survival. Clin Cancer Res 1995;1:1537-43.
27. Shintani S, Hino S, Nakashiro K, Hamakawa H. Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions. Gan To Kagaku Ryoho 2006;33:357-60.
28. Tono T, Takahashi H, Kanoh T, Nakano Y, Tamagaki S, Yasue A, et al. Evaluation of chemosensitivity testing by CD-DST and TS and DPD activity in cases of colorectal liver. Gan To Kagaku Ryoho 2001;28:1523-6.